Literature DB >> 22238348

Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF.

Randolf J Kerschbaumer1, Manfred Rieger, Dirk Völkel, Didier Le Roy, Thierry Roger, Jurate Garbaraviciene, Wolf-Henning Boehncke, Jürgen Müllberg, Rene M Hoet, Clive R Wood, Gerhard Antoine, Michael Thiele, Helga Savidis-Dacho, Michael Dockal, Hartmut Ehrlich, Thierry Calandra, Friedrich Scheiflinger.   

Abstract

The macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that recently emerged as an attractive therapeutic target for a variety of diseases. A diverse panel of fully human anti-MIF antibodies was generated by selection from a phage display library and extensively analyzed in vitro. Epitope mapping studies identified antibodies specific for linear as well as structural epitopes. Experimental animal studies revealed that only those antibodies binding epitopes within amino acids 50-68 or 86-102 of the MIF molecule exerted protective effects in models of sepsis or contact hypersensitivity. Within the MIF protein, these two binding regions form a β-sheet structure that includes the MIF oxidoreductase motif. We therefore conclude that this β-sheet structure is a crucial region for MIF activity and a promising target for anti-MIF antibody therapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22238348      PMCID： PMC3293543          DOI： 10.1074/jbc.M111.329664

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


  63 in total

1.  Structure activity studies of the cytokine macrophage migration inhibitory factor (MIF) reveal a critical role for its carboxy terminus.

Authors:  R Mischke; A Gessner; A Kapurniotu; S Jüttner; R Kleemann; H Brunner; J Bernhagen
Journal:  FEBS Lett       Date:  1997-09-08       Impact factor: 4.124

2.  The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction.

Authors:  E Rosengren; R Bucala; P Aman; L Jacobsson; G Odh; C N Metz; H Rorsman
Journal:  Mol Med       Date:  1996-01       Impact factor: 6.354

3.  Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice.

Authors:  A Mikulowska; C N Metz; R Bucala; R Holmdahl
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

4.  Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria.

Authors:  T Calandra; L A Spiegel; C N Metz; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

5.  Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor.

Authors:  K Bendrat; Y Al-Abed; D J Callaway; T Peng; T Calandra; C N Metz; R Bucala
Journal:  Biochemistry       Date:  1997-12-09       Impact factor: 3.162

6.  Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites.

Authors:  Peter D Senter; Yousef Al-Abed; Christine N Metz; Fabio Benigni; Robert A Mitchell; J Chesney; Jianlin Han; Carlos G Gartner; Sidney D Nelson; George J Todaro; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

7.  Immunosuppressive activities of recombinant glycosylation-inhibiting factor mutants.

Authors:  T Tomura; H Watarai; N Honma; M Sato; A Iwamatsu; Y Kato; R Kuroki; T Nakano; T Mikayama; K Ishizaka
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

8.  Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor.

Authors:  M Swope; H W Sun; P R Blake; E Lolis
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

9.  Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase.

Authors:  R Kleemann; A Kapurniotu; R W Frank; A Gessner; R Mischke; O Flieger; S Jüttner; H Brunner; J Bernhagen
Journal:  J Mol Biol       Date:  1998-07-03       Impact factor: 5.469

10.  Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis.

Authors:  M Bozza; A R Satoskar; G Lin; B Lu; A A Humbles; C Gerard; J R David
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307
View more
  30 in total

Review 1.  D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family.

Authors:  Melanie Merk; Robert A Mitchell; Stefan Endres; Richard Bucala
Journal:  Cytokine       Date:  2012-04-14       Impact factor: 3.861

2.  Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Authors:  Amanda Sparkes; Patrick De Baetselier; Lea Brys; Inês Cabrito; Yann G-J Sterckx; Steve Schoonooghe; Serge Muyldermans; Geert Raes; Richard Bucala; Peter Vanlandschoot; Jo A Van Ginderachter; Benoît Stijlemans
Journal:  FASEB J       Date:  2018-01-25       Impact factor: 5.191

3.  Structural Plasticity in the C-Terminal Region of Macrophage Migration Inhibitory Factor-2 Is Associated with an Induced Fit Mechanism for a Selective Inhibitor.

Authors:  Georgios Pantouris; Richard Bucala; Elias J Lolis
Journal:  Biochemistry       Date:  2018-06-12       Impact factor: 3.162

4.  Transcription factor ICBP90 regulates the MIF promoter and immune susceptibility locus.

Authors:  Jie Yao; Lin Leng; Maor Sauler; Weiling Fu; Junsong Zheng; Yi Zhang; Xin Du; Xiaoqing Yu; Patty Lee; Richard Bucala
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

5.  Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.

Authors:  Vinay Pasupuleti; Weinan Du; Yashi Gupta; I-Ju Yeh; Monica Montano; Cristina Magi-Galuzzi; Scott M Welford
Journal:  J Biol Chem       Date:  2013-12-19       Impact factor: 5.157

6.  MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis.

Authors:  Seung-Ah Yoo; Lin Leng; Bum-Joon Kim; Xin Du; Pathricia V Tilstam; Kyung Hee Kim; Jin-Sun Kong; Hyung-Ju Yoon; Aihua Liu; Tian Wang; Yan Song; Maor Sauler; Jurgen Bernhagen; Christopher T Ritchlin; Patty Lee; Chul-Soo Cho; Wan-Uk Kim; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-21       Impact factor: 11.205

7.  Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential.

Authors:  Joshua Bloom; Christine Metz; Saisha Nalawade; Julian Casabar; Kai Fan Cheng; Mingzhu He; Barbara Sherry; Thomas Coleman; Thomas Forsthuber; Yousef Al-Abed
Journal:  J Biol Chem       Date:  2016-10-28       Impact factor: 5.157

8.  A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity.

Authors:  Pathricia Veronica Tilstam; Georgios Pantouris; Michael Corman; Monica Andreoli; Keyvan Mahboubi; Gary Davis; Xin Du; Lin Leng; Elias Lolis; Richard Bucala
Journal:  J Biol Chem       Date:  2019-10-02       Impact factor: 5.157

9.  High expression levels of macrophage migration inhibitory factor sustain the innate immune responses of neonates.

Authors:  Thierry Roger; Anina Schneider; Manuela Weier; Fred C G J Sweep; Didier Le Roy; Jürgen Bernhagen; Thierry Calandra; Eric Giannoni
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

Review 10.  Emerging Systemic Therapies for Colorectal Cancer.

Authors:  Christine M Veenstra; John C Krauss
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.